Methotrexate and Mizoribine Combination

The combination of methotrexate (MTX) and mizoribine (MZR) is a therapeutic approach used primarily for rheumatoid arthritis patients who have an inadequate response to methotrexate alone. This combination therapy has shown promising results in clinical studies, with significant improvements in disease activity scores and other clinical parameters.\n\nMethotrexate is a well-established disease-modifying anti-rheumatic drug (DMARD) that works through multiple mechanisms, including inhibition of dihydrofolate reductase, promotion of adenosine release, and possibly inhibition of JAK/STAT pathway signaling[6][8][9]. Mizoribine is an oral immunosuppressive agent that inhibits inosine monophosphate dehydrogenase (IMPDH), an enzyme involved in purine biosynthesis[4][10].\n\nWhen used together, these medications appear to have synergistic effects. Studies have shown that low-dose mizoribine pulse therapy in combination with methotrexate provides both clinical and economic benefits for rheumatoid arthritis patients who don't respond adequately to methotrexate alone[2][3]. The combination has demonstrated significant improvements in Disease Activity Score 28 (DAS28) after 8-24 weeks of treatment, with 60% of patients achieving moderate responses and 8% achieving good responses in one study[2].\n\nThe combination therapy has also been investigated for its effects on osteoclastogenesis, with research suggesting synergistic inhibitory effects[5]. Additionally, mizoribine has shown comparable efficacy to methotrexate with potentially fewer side effects in treating polymyalgia rheumatica[4].\n\nRegarding safety, the combination appears to be generally well-tolerated, though potential side effects include infections, liver enzyme elevations, and gastrointestinal symptoms[2][4]. It's worth noting that the risk or severity of adverse effects can be increased when methotrexate is combined with mizoribine[10].\n\nThis combination therapy represents an important treatment option for patients with rheumatoid arthritis who don't respond adequately to methotrexate monotherapy, offering improved disease control while maintaining a manageable safety profile.

Other names

MTX and MZR Combination